Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST)

被引：0

作者：

Blay, Jean-Yves

Molimard, Mathieu

Cropet, Claire

Domont, Julien

Toulmonde, Maud

Bompas, Emmanuelle

Cassier, Philippe Alexandre

Ray-Coquard, Isabelle Laure

Rios, Maria

Adenis, Antoine

Italiano, Antoine

Le Cesne, Axel

Bouche, Olivier

Mir, Olivier

Duffaud, Florence

Bertucci, Francois

Isambert, Nicolas

Belleville, Aurelie

Gautier, Julien

Perol, David

机构：

[1] Ctr Leon Berard, Dept Med, F-69373 Lyon, France

[2] Grp Hosp Pellegrin, Bordeaux, France

[3] Ctr Leon Berard, Unite Biostat & Evaluat Therapeut, Direct Rech & Innovat, F-69373 Lyon, France

[4] Inst Gustave Roussy, Villejuif, France

[5] Inst Bergonie, Dept Med Oncol, Bordeaux, France

[6] Ctr Rene Gauducheau, Dept Med Oncol, St Herblain, France

[7] Ctr Leon Berard, F-69373 Lyon, France

[8] Ctr A Vautrin, Nancy, France

[9] Ctr Oscar Lambret, Dept Med Oncol, F-59020 Lille, France

[10] CLCC Inst Bergonie, Bordeaux, France

[11] Ctr Hosp Univ Robert Debre, Reims, France

[12] La Timone Univ Hosp, Marseilles, France

[13] Inst J Paoli I Calmettes, F-13009 Marseille, France

[14] Ctr Georges Francois Leclerc, Dijon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10506

引用

下载

页数：1

共 39 条

[31] Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial.
Vignani, Francesca
Tambaro, Rosa
De Giorgi, Ugo
Giannatempo, Patrizia
Bimbatti, Davide
Carella, Claudia
Stellato, Marco
Atzori, Francesco
Aieta, Michele
Masini, Cristina
Hamzaj, Alketa
Ermacora, Paola
Veccia, Antonello
Pignata, Sandro
Lolli, Cristian
Procopio, Giuseppe
Pierantoni, Francesco
Zonno, Antonia
Santini, Daniele
Di Maio, Massimo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[32] A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastroesophageal junction (G/GEJ) cancer
Moehler, Markus H.
Cho, Jae Yong
Kim, Yeul Hong
Kim, Jin Won
Di Bartolomeo, Maria
Ajani, Jaffer A.
Yamaguchi, Kensei
Balogh, Agnes
Kong-Sanchez, Maria Teresa
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.
Le Cesne, Axel
Blay, Jean-Yves
Cupissol, Didier
Italiano, Antoine
Delcambre, Corinne
Penel, Nicolas
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[34] Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT plus gastrointestinal stromal tumors (GIST).
von Mehren, M.
Heinrich, M. C.
Joensuu, H.
Blanke, C. D.
Wehrle, E.
Demetri, G. D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[35] CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
Chen, Eric Xueyu
Jonker, Derek J.
Loree, Jonathan M.
Kennecke, Hagen F.
Berry, Scott R.
Couture, Felix
Ahmad, Chaudhary E.
Goffin, John R.
Kavan, Petr
Harb, Mohammed
Colwell, Bruce
Samimi, Setareh
Samson, Benoit
Abbas, Tahir
Aucoin, Nathalie
Aubin, Francine
Koski, Sheryl L.
Wei, Alice Chia-chi
Tu, Dongsheng
O'Callaghan, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy
Vignani, F.
Hamzaj, A.
De Giorgi, U.
Tambaro, R.
Basso, U.
Gamba, T.
Ermacora, P.
Santini, D.
Capacci, S.
Casadei, C.
Pignata, S.
Bimbatti, D.
Giannatempo, P.
Atzori, F.
Cavanna, L.
Veccia, A.
Scandurra, G.
Doni, L.
Aieta, M.
Di Maio, M.
ANNALS OF ONCOLOGY, 2020, 31 : S607 - S607
[37] Sequential ipilimumab (Ipi) versus best supportive care (BSC) following first-line chemotherapy (Ctx) in patients (pts) with unresectable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer: A randomized, open-label, two-arm, phase II trial (CA184-162) of immunotherapy as a maintenance concept
Moehler, Markus Hermann
Kim, Yeul Hong
Tan, Iain B.
Balogh, Agnes
Sanchez, Teresa Kong
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[38] SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) plus bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results
Mayer, E.
Kozloff, M.
Qamar, R.
Klencke, B.
Balkissoon, J.
Parmar, H.
Samant, M.
Burstein, H. J.
CANCER RESEARCH, 2009, 69 (02) : 239S - 240S
[39] Final analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer
Arpino, Grazia
de la Haba-Rodriguez, Juan
Ferrero, Jean-Marc
De Placido, Sabino
Klingbiel, Dirk
Revelant, Valentine
Wohlfarth, Christine
Poppe, Raf
Rimawi, Mothaffar F.
CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 →